Patients Practitioners Medicines About Novo Nordisk Contact News and videos Novo Nordisk / Medicines / Diabetes / Xultophy ® (insulin degludec / liraglutide) Medicines Diabetes Fiasp ® (insulin aspart) GlucaGen ® (glucagon) Insulatard ® (isophane (NPH) human insulin) Levemir ® (insulin detemir) NovoMix ® 30 (biphasic insulin aspart) NovoMix ® 50 (biphasic insulin aspart) NovoMix ® 70 (biphasic insulin aspart) NovoNorm ® (repaglinide) NovoRapid ® (insulin aspart) Ozempic ® (semaglutide) Rybelsus ® (semaglutide tablets) Ryzodeg ® (insulin degludec / insulin aspart) Tresiba ® (insulin degludec) Victoza ® (liraglutide) Xultophy ® (insulin degludec / liraglutide) Growth hormone Haemophilia Obesity Hormone Replacement Therapy Delivery systems and needles Availability abroad Xultophy ® (insulin degludec / liraglutide) What is Xultophy ® ? Xultophy ® contains two active substances that help your body to regulate blood sugar: Insulin degludec - a long-acting basal insulin that lowers your blood sugar. Liraglutide - a 'GLP-1 analogue' that helps your body make more insulin during meals and reduces the amount of sugar your body makes itself. Who is Xultophy ® for ? Xultophy ® is indicated for the treatment of adults with diabetes mellitus type-2 in order to improve the glycemic control, in combination with oral glucose-lowering medications and do not provide adequate glycemic control these means alone or in combination with GLP-1 receptor agonists or basal insulin. Form of administration Xultophy ® is a clear and colorless solution and is available in a pre-filled Xultophy ® pen. Xultophy ® is administered in 'dose units'. The dose counter on the pen shows the number of dose units. One dose unit contains 1 unit of insulin degludec and 0.036 mg of liraglutide. The maximum daily dose Xultophy ® is 50 dose units (50 units of insulin and 1.8 mg degludec liraglutide). Patient information leaflet Xultophy ® 100 units / ml + 3.6 mg / ml solution for injection Are you using Xultophy ® ? Visit the patient website for helpful information on using Xultophy ® . read more Are you a practitioner? For more information about Xultophy ®, visit the practitioner website . read more Who we are Novo Nordisk is an international company with over 95 years of experience in diabetes care. The head office is located in Denmark. The company offers a wide range of innovative medicines, advanced delivery systems and services to optimize the care and treatment of people with diabetes. In addition, Novo Nordisk is a leader in coagulation disorders, growth hormone therapy and hormone replacement therapy. Novo Nordisk has approximately 43,100 employees in 80 countries and is represented in more than 170 countries. Novo Nordisk websites novonordisk.com Or choose: Local websites Novo Nordisk worldwide © Novo Nordisk BV 2020 Privacy Statement Disclaimers Processing of personal data, side effects and other safety information Cookie Settings